Piper Sandler Starts Coverage on BioAge Labs With Buy Rating and $73 Target
Piper Sandler initiates coverage of BioAge Labs with an Overweight rating, highlighting strong early data for its lead drug BGE-102 and key upcoming catalysts.
Piper Sandler initiates coverage of BioAge Labs with an Overweight rating, highlighting strong early data for its lead drug BGE-102 and key upcoming catalysts.
Citi analyst upgrades BioAge Labs to Buy with $10 price target, citing BGE-102 obesity drug as potentially game-changing treatment option.